Research Topics
Species | M A ShippSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltratePrzemyslaw Juszczynski
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Mol Cell Biol 26:5348-59. 2006..IFN-gamma-induced BAL1/BBAP expression contributes to the molecular signature of HR DLBCLs and highlights the interplay between the inflammatory infiltrate and malignant B cells in these tumors...
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learningMargaret A Shipp
Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
Nat Med 8:68-74. 2002..Our data indicate that supervised learning classification techniques can predict outcome in DLBCL and identify rational targets for intervention...- BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migrationR C Aguiar
Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Blood 96:4328-34. 2000..Blood. 2000;96:4328-4334).. - Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomasK Takeyama
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Oncogene 27:318-22. 2008..These studies highlight the role of 53BP1 copy loss in primary human DLBCLs and the value of integrative analyses in detecting this genetic lesion in human tumors... - Stromelysin-3 suppresses tumor cell apoptosis in a murine modelE Wu
Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Cell Biochem 82:549-55. 2001..Because STR-3 is secreted as an active enzyme rather than a proform, subsequent 45 kDa to 35 kDa STR-3 processing may represent a novel mechanism for regulating enzymatic activity... - Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survivalOrion M Howard
Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 20:1288-94. 2002..Nevertheless, rituximab and combination chemotherapy may transiently clear PB or BM of detectable tumor cells, prompting additional consideration of antibody-based in vivo purging in subsequent clinical trials... - FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypesHidenobu Takahashi
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 12:3265-71. 2006.... - NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypesFriedrich Feuerhake
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 106:1392-9. 2005..In this large series of primary MLBCLs and DLBCLs, NFkappaB activation was not associated with amplification of the cREL locus, suggesting alternative pathogenetic mechanisms... - High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351Bruce A Peterson
University of Minnesota, Minneapolis, MN 55455, USA
Leuk Lymphoma 48:870-80. 2007..Six patients have developed AML or MDS. In view of the substantial toxicity accompanying high dose CHOP, the observed outcome suggests that its efficacy is not sufficient to make further study feasible... - BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanismsSamir Parekh
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Blood 110:2067-74. 2007..Taken together, these results show that BCL6 regulates distinct transcriptional programs through the SMRT/N-CoR and MTA3 corepressors, respectively, and provides a basis for combinatorial therapeutic targeting of BCL6... - The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphomaPeter G Smith
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Blood 105:308-16. 2005.... - The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphomaKerry J Savage
Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 102:3871-9. 2003..In almost all cases, c-REL was localized to the nucleus, consistent with activation of the NF-kappa B pathway. These studies identify a molecular link between MLBCL and cHL and a shared survival pathway... - The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activityKunihiko Takeyama
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
J Biol Chem 278:21930-7. 2003..Consistent with this idea, BBAP and DTX1 associate via their unique N termini, resulting in enhanced self-ubiquitination... - Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory responseStefano Monti
The Broad Institute, Cambridge, MA, USA
Blood 105:1851-61. 2005..These studies identify tumor microenvironment and host inflammatory response as defining features in DLBCL and suggest rational treatment targets in specific DLBCL subsets... - Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphomaMichael J Robertson
Indiana University Medical Center, Indianapolis, IN, USA
J Clin Oncol 25:1741-6. 2007..We conducted a multicenter phase II study of a potent inhibitor of PKCbeta, enzastaurin, in patients with relapsed or refractory DLBCL... - Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphomaScott J Rodig
Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Am J Surg Pathol 31:106-12. 2007..Thus, the combined nuclear localization of c-Rel and the cellular expression of TRAF1 is a highly specific (specificity=98%) means to distinguish PMLBCL from DLBCL that is readily applicable to routine surgical pathology practice... - Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)Scott J Rodig
Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Clin Cancer Res 12:7174-9. 2006..The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed... - Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferationLinfeng Chen
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 108:3428-33. 2006..PTPROt overexpression also inhibited lymphoma cell proliferation and induced apoptosis in the absence of BCR cross-linking, suggesting that the phosphatase modulates tonic BCR signaling... - Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphomaLaura Pasqualucci
Institute for Cancer Genetics and 2The Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
J Exp Med 203:311-7. 2006..These findings point to a role for BLIMP1 as a tumor suppressor gene, whose inactivation may contribute to lymphomagenesis by blocking post-GC differentiation of B cells toward plasma cells... - Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphomaHidenobu Takahashi
Blood 107:844-5. 2006 - B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activityRicardo C T Aguiar
Division of Hematological Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
J Biol Chem 280:33756-65. 2005..BAL family members are the only described proteins with both PARP and macro domains, underscoring the potential functional significance of this unique combination... - Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachJeremy S Abramson
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 106:1164-74. 2005..Our increasing molecular understanding of the heterogeneous subsets within DLBCL will likely improve the current empiric therapy of DLBCL by identifying rational therapeutic targets in specific disease subtypes... - Case records of the Massachusetts General Hospital. Case 12-2005. A 30-year-old woman with a mediastinal massMargaret A Shipp
Division of Medical Oncology, Dana-Farber Cancer Institute, USA
N Engl J Med 352:1697-704. 2005 - Tumor cell-mediated induction of the stromal factor stromelysin-3 requires heterotypic cell contact-dependent activation of specific protein kinase C isoformsKrystel Louis
INSERM U526, IFR50, Faculté de Médecine Pasteur, 06107 Nice, France
J Biol Chem 280:1272-83. 2005..Altogether, our data emphasize signaling changes occurring in the tumor microenvironment that may define new stromal targets for therapeutic intervention... - SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphomaLinfeng Chen
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Blood 111:2230-7. 2008..Therefore, SYK-dependent tonic BCR signaling is an important and potentially targetable survival pathway in some, but not all, DLBCLs. In addition, R406-sensitive DLBCLs can be identified by their transcriptional profiles...
Research Grants
- STROMELYSIN 3 AND THE TUMOR MICROENVIRONMENTMargaret Shipp; Fiscal Year: 2002....
- PROGRAM PROJECT GRANT: Molecular Targets of Germinal Center B-Cell LymphomasMargaret Shipp; Fiscal Year: 2007....